A new site will add 120,000L biomanufacturing capacity to WuXi Biologics' global network by 2026.
It is expected to employ 1,500 research, development and manufacturing staff when complete; adding significantly to the 10,000 people the company already employs worldwide.
The company says the Singapore site will become a ‘critical part’ of its global supply chain network: and follows recent investments made in the US, Ireland, Germany and China.
The center will also support WuXi Biologics' Global Dual Sourcing strategy – a strategy to ensure that customer projects can be fulfilled at multiple facilities globally and thus mitigate potential risks.
Dr. Chris Chen, CEO of WuXi Biologics, said, "Singapore has established itself as one of the most advanced pharmaceutical hubs in the world. As a trusted partner to global healthcare companies and a strong contributor to the local community, WuXi Biologics' investment in the new CRDMO center will enhance the sustainable growth and success of the Singapore biotech ecosystem and enable the global biologics industry with a more robust supply chain.
"With the support of EDB and our local partners in Singapore, WuXi Biologics looks forward to moving ahead with this important project to enable global partners and benefit patients worldwide.”
WuXi Biologics' investment plan is supported by the Singapore Economic Development Board (EDB), which champions Singapore’s central Asian location, pro-business environment, infrastructure and innovation ecosystem.
The pharmaceutical sector’s manufacturing output has tripled since 2000: with some $12bn worth of products produced for global markets a year.
Dr. Beh Swan Gin, Chairman of EDB, said: "The investments will establish Singapore as a significant node in the company's global research, development and manufacturing network. It is a testament to Singapore's position as a global biopharmaceutical hub, and will strengthen our attractiveness to biotech innovators and start-ups."